[Maintaining independence. New protease inhibitor receives drug approval recommendation].
D002219:Carbamates; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D024921:Drug Resistance, Multiple, Viral / Q000187:drug effects; D004359:Drug Therapy, Combination; D005060:Europe; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D010755:Organophosphates / Q000009:adverse effects / Q000627:therapeutic use*; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D019562:Viral Load
D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D010755:Organophosphates; D013449:Sulfonamides; C426859:fosamprenavir
Unabhängigkeit bewahren. Neuer Proteaseinhibitor erhält Zulassungsempfehlung.